Alembic Pharmaceuticals received final USFDA approval for its Levothyroxine Sodium Tablets in 12 strengths.
The approved generic drug is equivalent to AbbVie's Synthroid, targeting a US market of $1.87 billion.
This marks Alembic's 239th ANDA approval from USFDA, strengthening its US generic portfolio.